Jhonny Peralta, Jim Leyland, Tony Randazzo

Looking at the potentially suspended Biogenesis players

76 Comments

Let’s run down the list of players connected to Tony Bosch’s Biogenesis clinic as MLB is reportedly preparing to issue 50- or 100-game suspensions. Listed below are players whose names are found in the Biogenesis documents. Other major leaguers may well be involved, as some of Bosch’s clients were listed in code. Since Bosch is set to cooperate with MLB in its investigation, this list could grow significantly longer soon. According to ESPN’s Outside the Lines, MLB is preparing to suspend players who purchased illegal substances from Bosch for 50 or 100 games, even if it means ruining the season in the process.

The Players

Alex Rodriguez (3B Yankees): Sidelined since Opening Day following offseason hip surgery, Rodriguez, who admitted to using steroids a decade ago but was never suspended, has been aiming to return to the Yankees lineup in July. Players suspended for steroid use while on the disabled list are able to serve those suspensions while injured, so if Rodriguez were to receive a 50-game ban in the near future, he could still return in August. A 100-game ban, on the other hand, would essentially end his season.

Ryan Braun (OF Brewers): Braun was originally set to be suspended for a positive PED test in Dec. 2011, only to have it wiped out on appeal. Of course, that was all supposed to go on behind closed doors, but it leaked to the media not long after Braun won NL MVP honors in 2011. This year, Braun is hitting .294 with nine homers for a disappointing Brewers team. He’s currently third in the outfield in the NL All-Star balloting, putting him in position for a spot in the starting lineup in the Midseason Classic.

Melky Cabrera (OF Blue Jays), Bartolo Colon (RHP Athletics) and Yasmani Grandal (C Padres): All three players here tested positive for steroids before MLB had any knowledge of Bosch’s operation and have already served 50-game suspensions. If MLB is going to try banning A-Rod and Braun for 100 games (50 games for cheating and 50 games for lying about it), then it could deliver additional 50-game suspensions to this trio. Still, that seems like quite a reach. These guys have already done their time.

Nelson Cruz (OF Rangers): The 32-year-old Cruz has a ton to lose here, since he’ll be a free agent at season’s end. His team would greatly suffer without him as well, and his absence could lead to Jurickson Profar being tried in the outfield. Cruz is batting .267 with 13 homers and 39 RBI this year, making him a candidate for AL All-Star honors.

Jhonny Peralta (SS Tigers): The Tigers might be the contender most adversely affected should these penalties come to pass; Peralta has been the AL’s top offensive shortstop this year, hitting .332 with six homers and 26 RBI, and the Tigers just don’t have any decent options to fill his shoes. Utilityman Ramon Santiago is long past his prime, and Danny Worth is injured in Triple-A. Like Cruz, Peralta is also a free agent this winter.

Everth Cabrera (SS Padres): Cabrera led the NL in stolen bases with 44 last year, but he was still a rather anonymous figure outside of San Diego. This year, he’s been getting more attention, thanks in part to some added power. He has four homers in 57 games after hitting two in 115 games in 2012, and his OPS has climbed by more than 100 points. He’s still a force on the basepaths, too, leading the majors with 23 steals.

Francisco Cervelli (C Yankees): One can imagine Cervelli, who played in 178 games as the Yankees’ primary backup catcher from 2009-11, was looking for something a little extra last year after being banished to the minors and thus turned to Bosch for help. Following Russell Martin’s departure, he won the starting job this spring and was off to an excellent start (.269/.377/.500, three homers in 52 at-bats) before going down with a fractured right hand. Barring a suspension, he’s due to rejoin the Yankees lineup in late June.

Jesus Montero (C-DH Mariners): A former Yankees prospect, Montero was dealt to the Mariners prior to 2012 and had a decent rookie season last year, hitting .260 with 15 homers. This year, he was a huge bust as a starting catcher, hitting .208 with three homers in 101 at-bats, and he was sent back to Triple-A late last month. Just 23, he’s still a promising hitter, but his future is at first base or DH. He’s currently on the minor league DL after tearing knee cartilage.

Fernando Martinez (OF Astros): Martinez was once one of the game’s very best prospects while in the Mets chain, but he’s never been able to stay healthy and he’s now a long shot to enjoy a lengthy major league career. After hitting .182 in 11 games for the Astros earlier this year, he was dropped from the roster and cleared waivers. He’s now back in Triple-A.

Fautino De Los Santos (RHP free agent): De Los Santos was a strong prospect in the White Sox system before undergoing Tommy John surgery and converting to relief. He looked like a fine bullpen arm as a rookie in 2011, striking out 43 batters in 33 1/3 innings for the A’s, but he showed up in 2012 which diminished stuff and has bounced around since. The Padres released him last month.

Jordan Norberto (LHP free agent): Norberto had a 2.77 ERA in 52 innings of relief work for the A’s last year, but he struggled this spring and got hurt. Oakland released him last month.

Cesar Puello (OF Mets): Puello, 22, has been a breakout performer in the Mets system this year, hitting .302/.382/.521 with eight homers and 15 steals for Double-A Binghamton. That slugging percentage is nearly 100 points higher than his previous career high.

Unlikely to be suspended

Gio Gonzalez (LHP Nationals): Gonzalez is believed to have been a Biogenesis buyer, but only of legal substances. Two sources told ESPN that Gonzalez is probably off the hook as far as any punishments go.

Robinson Cano (2B Yankees): Cano’s known connection with Biogenesis is very tenuous: the spokeswoman for his charitable foundation was named in Bosch’s documents. That was enough to get Cano on MLB’s watchlist, but if anything more significant has turned up, the league has kept it quiet.

The Marlins have made a “monster offer” for Kenley Jansen

LOS ANGELES, CA - OCTOBER 18:  Kenley Jansen #74 of the Los Angeles Dodgers delivers a pitch against the Chicago Cubs in the eighth inning of game three of the National League Championship Series at Dodger Stadium on October 18, 2016 in Los Angeles, California.  (Photo by Sean M. Haffey/Getty Images)
Getty Images
1 Comment

OXON HILL, MD — The morning after Aroldis Chapman signed for a record $86 million, the Miami Marlins are reported to have made similarly lucrative offer to the other top free agent closer, Kenley Jansen.

Jeff Passan of Yahoo says that the Marlins have made “a monster offer” of five years and more than $80 million to Jansen. This despite the fact that the club is coming off of a 79-win season and, tragically, lost their top pitcher Jose Fernandez in a fatal boating accident, which will substantially harm their competitive prospects. While it seems like a stretch to say that the Yankees will compete for a playoff spot, thereby making such an historically large investment in a closer a bit suspect, the Marlins doing so is even more questionable.

Meanwhile, the Nationals are said to be interested in Jansen as well, though Chelsea Janes of the Washington Post says the Nats are “uncomfortable” with the financial commitment signing him would require.

Jansen most recently pitched for the Dodgers and there have been no reports that they’re totally out on him, but there has been nothing to suggest that they are pushing hard for him either.

Jansen, 29, finished this past season with 47 saves, a 1.83 ERA, and a 104/11 K/BB ratio in 68.2 innings. That’s not quite Aroldis Chapman good, but he seems poised to collect something close to Aroldis Chapman money.

The Yankees are paying $86 million for a one-inning reliever

chapman
18 Comments

OXON HILL, MD — The Yankees signing of Aroldis Chapman late Wednesday night came as something of a surprise. And the money — $86 million — was something of a shock. Yes, we knew that Chapman was going to break the bank and likely set a record as the highest paid relief pitcher in history, but seeing it in black and white like that is still rather jarring.

In the coming days, many people who attempt to analyze and contextualize this signing will do so by pointing to the 2016 playoffs and the unconventional use of relievers by Terry Francona and the Indians and Joe Maddon of the Cubs. They’ll talk about how the paradigm of bullpen use has shifted and how relief pitchers have taken on a new importance in today’s game. Chapman’s astronomical salary, therefore, will be described as somehow more reasonable and somewhat less shocking than it first seems.

Don’t buy that jive for a second.

Yes, Andrew Miller and, to some extent, Chapman himself were used unconventionally in the 2016 playoffs, but not long into the 2017 season we will see that as an exception, not the rule. And not just because Chapman showed himself unable to hold up to that level of use in the playoffs. It will be the exception because the Yankees have shown no inclination whatsoever to deviate from traditional bullpen usage in the past and there is no reason to expect that they will do so with Chapman in the future.

As you no doubt remember, the Yankees had Chapman, Dellin Betances and Andrew Miller for the first half of 2016. Such an imposing back end of a bullpen has rarely been seen in recent history. All of them, however, were used, more or less, as one-inning-a-piece guys and no real effort was ever made to break any bullpen usage paradigms or to shorten games the way many applauded Terry Francona for doing in the playoffs.

Miller pitched 44 games for the Yankees, totaling 45.1 innings. He pitched more than a single inning on only three occasions. Chapman pitched 31 games for the Yankees, amassing 31.1 innings. He was used for more than one inning only twice. Betances worked in 73 games, totaling 73 innings. On 11 occasions he pitched more than one inning.  It was unconventional for a team to have three relievers that good, but they were not, in any way, used unconventionally. Nor is there any reason to expect Chapman to be used unconventionally in 2017, especially given that Miller is not around and Chapman has shown no real ability to be stretched for multiple innings for a sustained period.

None of which is to say that having Chapman around is a bad thing or that he is any less of a closer than his reputation suggests. It’s merely to say that the Yankees paying Chapman unprecedented money for a closer should not be justified by the alleged new importance of relief pitchers or that changing role for them we heard so much about in the playoffs. Indeed, I suspect that that changing role applies only to pitcher use in the playoffs. And I do not suspect that this transaction alone pushes the Yankees into serious playoff contention, making that temporary unconventionality something of a moot point in New York for the foreseeable future.

It is almost certain that the Yankees are paying $86 million for the same one-inning closer Aroldis Chapman has been for his entire seven-year career. His contract may or may not prove to be a good one for New York based on how he performs, but don’t let anyone tell you now, in Decemeber 2016, that it’s better than you think because Chapman will somehow transform into a 1970s-style relief ace or something.